| pubmed-article:3652526 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0019628 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:3652526 | lifeskim:mentions | umls-concept:C1627358 | lld:lifeskim |
| pubmed-article:3652526 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3652526 | pubmed:dateCreated | 1987-11-9 | lld:pubmed |
| pubmed-article:3652526 | pubmed:abstractText | Changes in monocyte cell-surface markers were assessed during treatment of patients with beta-interferon (beta-IFN). Immediately after isolation monocytes were analysed using monoclonal antibodies and flow cytometry. After 2 days of beta-IFN significant increases in major histocompatibility complex (MHC) related cell-surface products were observed while no changes in Leu-M3, a non-MHC associated monocyte-specific marker, were found. The most striking increases were (1) the percent of monocytes positive for HLA-DQ (mean increase = 19.7%); (2) the relative amount of monocyte-surface HLA-DR (mean increase = 10.1 mean fluorescence intensity (MFI) units); and (3) the relative amount of monocyte-surface beta 2-microglobulin (mean increase = 7.7 MFI units). Increases in MHC expression over baseline were greater after 2 days of beta-IFN treatment than after 14 days of IFN. Thus beta-IFN, produced by recombinant DNA technology and purified to homogeneity, increased surface MHC expression on monocytes in vivo. Additionally, levels of 2-5A synthetase, a type-I IFN-induced enzyme, were significantly increased in patient peripheral blood mononuclear cells after treatment. Increases in 2-5A synthetase were found to correlate with increases in MHC expression suggesting a common mechanism for induction. Flow cytometry can in the future be used to correlate changes in MHC expression with therapeutic response. | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3652526 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3652526 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3652526 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3652526 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:3652526 | pubmed:issn | 0009-9104 | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:BordenE CEC | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:JordanR LRL | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:MerrittJ AJA | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:PaulnockD MDM | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:SpearG TGT | lld:pubmed |
| pubmed-article:3652526 | pubmed:author | pubmed-author:MeltzerD MDM | lld:pubmed |
| pubmed-article:3652526 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3652526 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:3652526 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3652526 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3652526 | pubmed:pagination | 107-15 | lld:pubmed |
| pubmed-article:3652526 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:meshHeading | pubmed-meshheading:3652526-... | lld:pubmed |
| pubmed-article:3652526 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3652526 | pubmed:articleTitle | Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. | lld:pubmed |
| pubmed-article:3652526 | pubmed:affiliation | Department of Human Oncology, University of Wisconsin, Madison. | lld:pubmed |
| pubmed-article:3652526 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3652526 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3652526 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3652526 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3652526 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3652526 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3652526 | lld:pubmed |
